Agonistic CD28 antigen binding molecules targeting Her2
US12049515B2 · kind B2 · utility
0Cited by
27References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2021 |
| Grant date | Jul 30, 2024 |
| Priority date | — |
| Expiry date | Aug 25, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.